Topical Delivery IP MedPharm-US owns a substantial patent portfolio around topical and transdermal drug delivery systems (including MedSpray, MedRo, MedTherm, AquaRMed) and is actively seeking licenses. This presents a sales opportunity to pharmaceutical developers seeking validated, patent-protected delivery platforms to accelerate their topical formulations.

Pipeline Licensing The company commercializes its delivery technologies through partnerships and is actively pursuing licensing deals with third parties. Targeted outreach to biotech and pharma companies developing skin, nail, mucosal, ocular, nasal, or pulmonary therapies could yield licensing collaborations or co-development arrangements.

Niche Expertise Specialization in performance testing and biological models for topical and transdermal products positions MedPharm-US as a potential CRO or strategic partner for studies required to advance early-stage assets toward regulatory approval, offering opportunities for sponsored research and pilot testing engagements.

Growth-Ready Revenue Current revenue is in the range of 1M to 10M with a modest employee base, suggesting an adaptable, partner-focused organization capable of rapid project onboarding and scalable collaboration models for new clients seeking specialized formulation development and testing services.

Strategic Fit with Dermal Players Comparable company context indicates alignment with larger dermal and cannabis-derived product ecosystems. Prospects include collaborations with smaller dermatology-focused brands or larger players exploring topical/dermal delivery expansions, leveraging MedPharm-US’s patent-backed platforms and testing capabilities.